Tehran, Farabi Eye Hospital

Purpose: To compare the effect of tissue plasminogen activator (TPA) and aspirin in patients with central retinal vein occlusion. Methods: A prospective interventional study was conducted on patients with central retinal vein occlusion of less than 28 days ' duration. Patients in the TPA group received 100 μg intravitreal tissue plasminogen activator and the patients who declined intravitreal injection were considered as Aspirin group. Patients were followed up for 6 months. Results: sixty five patients were enrolled, 19 in the TPA group and 46 in the Aspirin group. The mean 6-month change in visual acuity for TPA-treated patients was-0.29±0.42 (range:-1.4 to +0.5) while in the Aspirin group, it was 0.28±0.79 with a range of-1 to +2.5. TPA group had a significantly better visual improvement in comparison to Aspirin group (P< 0.0005). Conclusion: Intravitreal tissue plasminogen activator can be injected safely and easily. Patients treated with intravitreal tissue plasminogen activator within 28 days of the onset of central retina